Webster Cavenee, Ph.D. - Publications

Affiliations: 
Cellular & Moecular Medicine Ludwig Institute for Cancer Research, San Diego 
Area:
FKHR gene, EGFRvIII
Website:
http://hem-onc.ucsd.edu/faculty/cavenee.shtml

222 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, Zhang W, Villa GR, Wu S, Quehenberger O, Yong WH, ... ... Cavenee WK, et al. Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism. PMID 31303424 DOI: 10.1016/j.cmet.2019.06.014  0.48
2019 Staquicini FI, Smith TL, Tang FHF, Gelovani JG, Giordano RJ, Libutti SK, Sidman RL, Cavenee WK, Arap W, Pasqualini R. Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies. Cancer Gene Therapy. PMID 31130731 DOI: 10.1038/s41417-019-0101-2  0.32
2019 Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, ... ... Cavenee WK, et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 35: 816. PMID 31085179 DOI: 10.1016/j.ccell.2019.04.011  0.48
2019 Orellana L, Thorne AH, Lema R, Gustavsson J, Parisian AD, Hospital A, Cordeiro TN, Bernadó P, Scott AM, Brun-Heath I, Lindahl E, Cavenee WK, Furnari FB, Orozco M. Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. Proceedings of the National Academy of Sciences of the United States of America. PMID 31028138 DOI: 10.1073/pnas.1821442116  0.48
2019 Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, ... ... Cavenee WK, et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. PMID 30827889 DOI: 10.1016/j.ccell.2019.01.020  0.48
2019 Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, Chesnokova A, Cavenee WK, Furnari FB, Ljubimov VA, Shatalova ES, Wagner S, Li D, Mamelak AN, Bannykh SI, Patil CG, et al. Blockade of a laminin-411 - Notch axis with CRISPR/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment crosstalk. Cancer Research. PMID 30659021 DOI: 10.1158/0008-5472.CAN-18-2725  0.48
2019 Masui K, Onizuka H, Cavenee WK, Mischel PS, Shibata N. Metabolic reprogramming in the pathogenesis of glioma: Update. Neuropathology : Official Journal of the Japanese Society of Neuropathology. PMID 30609184 DOI: 10.1111/neup.12535  0.44
2018 Chohan MO, Marchiò S, Morrison LA, Sidman RL, Cavenee WK, Dejana E, Yonas H, Pasqualini R, Arap W. Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review. Jama Neurology. PMID 30476961 DOI: 10.1001/jamaneurol.2018.3634  0.32
2018 Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, et al. Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death and Differentiation. PMID 30323273 DOI: 10.1038/s41418-018-0213-5  0.44
2018 Talukdar S, Pradhan AK, Bhoopathi P, Shen XN, August LA, Windle JJ, Sarkar D, Furnari FB, Cavenee WK, Das SK, Emdad L, Fisher PB. Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin. Autophagy. 1-2. PMID 30118375 DOI: 10.1080/15548627.2018.1502564  0.48
2018 Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee WK, Furnari FB. Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications. 9: 16217. PMID 29799523 DOI: 10.1038/ncomms16217  0.48
2018 Talukdar S, Pradhan AK, Bhoopathi P, Shen XN, August LA, Windle JJ, Sarkar D, Furnari FB, Cavenee WK, Das SK, Emdad L, Fisher PB. MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 29760085 DOI: 10.1073/pnas.1721650115  0.48
2018 Benitez JA, Zanca C, Ma J, Cavenee WK, Furnari FB. Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts. Journal of Visualized Experiments : Jove. PMID 29757276 DOI: 10.3791/57448  0.48
2018 Sun L, Yu S, Xu H, Zheng Y, Lin J, Wu M, Wang J, Wang A, Lan Q, Furnari F, Cavenee W, Purow B, Li M. FHL2 interacts with EGFR to promote glioblastoma growth. Oncogene. PMID 29321665 DOI: 10.1038/s41388-017-0068-0  0.48
2017 Liu F, Mischel PS, Cavenee WK. Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. Npj Precision Oncology. 1: 1. PMID 29872691 DOI: 10.1038/s41698-017-0005-2  0.44
2017 Teixeira AA, Marchiò S, Dias-Neto E, Nunes DN, da Silva IT, Chackerian B, Barry M, Lauer RC, Giordano RJ, Sidman RL, Wheeler CM, Cavenee WK, Pasqualini R, Arap W. Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses. Embo Molecular Medicine. PMID 28751581 DOI: 10.15252/emmm.201708072  0.32
2017 Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, ... ... Cavenee WK, et al. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes & Development. PMID 28724615 DOI: 10.1101/gad.300079.117  0.48
2017 Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee WK, Furnari FB. PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications. 8: 15223. PMID 28497778 DOI: 10.1038/ncomms15223  0.48
2017 Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. PMID 28178237 DOI: 10.1038/nature21356  0.48
2016 Kegelman TP, Wu B, Das SK, Talukdar S, Beckta JM, Hu B, Emdad L, Valerie K, Sarkar D, Furnari FB, Cavenee WK, Wei J, Purves A, De SK, Pellecchia M, et al. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proceedings of the National Academy of Sciences of the United States of America. PMID 28011764 DOI: 10.1073/pnas.1616100114  0.48
2016 Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, Ljubimov VA, Chesnokova A, Kramerov AA, Ding H, Falahatian V, Mashouf L, Fox I, Black KL, Holler E, et al. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 27825958 DOI: 10.1016/j.jconrel.2016.11.001  0.48
2016 Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, ... ... Cavenee WK, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. PMID 27746144 DOI: 10.1016/j.ccell.2016.09.008  0.48
2016 Masui K, Shibata N, Cavenee WK, Mischel PS. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. PMID 27427440 DOI: 10.1002/bies.201600026  0.44
2016 Masui K, Cavenee WK, Mischel PS. Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathology. PMID 27295313 DOI: 10.1007/s10014-016-0265-5  0.44
2016 Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 131: 803-20. PMID 27157931 DOI: 10.1007/s00401-016-1545-1  0.92
2016 Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, ... ... Cavenee WK, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73. PMID 27070703 DOI: 10.1016/j.ccell.2016.03.012  0.92
2015 Masui K, Cavenee WK, Mischel PS. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathology (Zurich, Switzerland). 25: 755-9. PMID 26526943 DOI: 10.1111/bpa.12307  0.92
2015 Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, ... ... Cavenee WK, et al. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular Cell. PMID 26455392 DOI: 10.1016/j.molcel.2015.09.002  0.92
2015 Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the National Academy of Sciences of the United States of America. PMID 26170313 DOI: 10.1073/pnas.1511759112  0.92
2015 Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, ... ... Cavenee WK, et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proceedings of the National Academy of Sciences of the United States of America. PMID 26080435 DOI: 10.1073/pnas.1507882112  0.92
2015 Shen Y, Li J, Nitta M, Futalan D, Steed T, Treiber JM, Taich Z, Stevens D, Wykosky J, Chen HZ, Carter BS, Becher OJ, Kennedy R, Esashi F, Sarkaria JN, ... ... Cavenee WK, et al. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget. 6: 11751-67. PMID 26059434  0.92
2015 Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews. Cancer. 15: 302-10. PMID 25855404 DOI: 10.1038/nrc3918  0.92
2015 Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, ... ... Cavenee WK, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proceedings of the National Academy of Sciences of the United States of America. 112: 1107-12. PMID 25583476 DOI: 10.1073/pnas.1422640112  0.92
2015 Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Research. 75: 394-404. PMID 25432173 DOI: 10.1158/0008-5472.CAN-14-2004  0.92
2015 Costa ET, Barnabé GF, Li M, Dias AA, Machado TR, Asprino PF, Cavalher FP, Ferreira EN, Del Mar Inda M, Nagai MH, Malnic B, Duarte ML, Leite KR, de Barros AC, Carraro DM, ... ... Cavenee W, et al. Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals. Oncogene. 34: 1270-9. PMID 24662834 DOI: 10.1038/onc.2014.70  0.92
2014 Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biology & Medicine. 11: 255-63. PMID 25610711 DOI: 10.7497/j.issn.2095-3941.2014.04.004  0.92
2014 Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene. PMID 25347738 DOI: 10.1038/onc.2014.336  0.92
2014 Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, ... ... Cavenee WK, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. The Journal of Clinical Investigation. 124: 3741-56. PMID 25061874 DOI: 10.1172/JCI73093  0.92
2014 Kawashima N, Qu H, Lobaton M, Zhu Z, Sollogoub M, Cavenee WK, Handa K, Hakomori SI, Zhang Y. Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation. Oncology Letters. 7: 933-940. PMID 24944646 DOI: 10.3892/ol.2014.1887  0.92
2014 Masui K, Cavenee WK, Mischel PS. mTORC2 in the center of cancer metabolic reprogramming. Trends in Endocrinology and Metabolism: Tem. 25: 364-73. PMID 24856037 DOI: 10.1016/j.tem.2014.04.002  0.92
2014 Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, Carter BS, Kwon CH, Furnari F, Cavenee W, Elledge S, et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget. 5: 882-93. PMID 24658464  0.92
2014 Masui K, Cavenee WK, Mischel PS. mTORC2 dictates Warburg effect and drug resistance. Cell Cycle (Georgetown, Tex.). 13: 1053-4. PMID 24583874 DOI: 10.4161/cc.28377  0.92
2014 Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee WK. Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Research. 74: 1429-39. PMID 24436148 DOI: 10.1158/0008-5472.CAN-13-2117  0.92
2014 Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, ... ... Cavenee WK, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/science.1241328  0.92
2014 Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annual Review of Pathology. 9: 1-25. PMID 23937436 DOI: 10.1146/annurev-pathol-011110-130324  0.92
2014 Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee WK, Cheng SY. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. 33: 2504-12. PMID 23728337 DOI: 10.1038/onc.2013.198  0.92
2013 Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee WK. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biology & Medicine. 10: 192-205. PMID 24349829 DOI: 10.7497/j.issn.2095-3941.2013.04.003  0.92
2013 Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, ... ... Cavenee WK, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism. 18: 726-39. PMID 24140020 DOI: 10.1016/j.cmet.2013.09.013  0.92
2013 Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, ... ... Cavenee WK, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.CCR-13-0527  0.92
2013 Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, ... ... Cavenee WK, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 17: 1000-8. PMID 23707073 DOI: 10.1016/j.cmet.2013.04.013  0.92
2013 Iwanami A, Cloughesy TF, Cavenee WK, Mischel PS. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle (Georgetown, Tex.). 12: 1473-4. PMID 23624839 DOI: 10.4161/cc.24747  0.92
2013 Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, ... ... Cavenee WK, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery. 3: 534-47. PMID 23533263 DOI: 10.1158/2159-8290.CD-12-0502  0.92
2013 Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee WK, Mischel PS, Furnari FB, Thomas JB. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. Plos Genetics. 9: e1003253. PMID 23459592 DOI: 10.1371/journal.pgen.1003253  0.92
2013 Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 34: 725-38. PMID 23455378 DOI: 10.1093/carcin/bgt086  0.92
2013 Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44. PMID 23440206 DOI: 10.1073/pnas.1217602110  0.92
2013 Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, Aldape K, Cavenee WK, Bogler O, Furnari FB. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. International Journal of Cancer. Journal International Du Cancer. 132: 509-20. PMID 22729867 DOI: 10.1002/ijc.27690  0.92
2012 Cavenee WK. Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer. Cancer Prevention Research (Philadelphia, Pa.). 5: 1073-4. PMID 22911109 DOI: 10.1158/1940-6207.CAPR-12-0220  0.92
2012 Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, ... ... Cavenee WK, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America. 109: 14164-9. PMID 22891331 DOI: 10.1073/pnas.1211962109  0.92
2012 Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes & Development. 26: 756-84. PMID 22508724 DOI: 10.1101/gad.187922.112  0.48
2012 Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R, Sarkaria JN, Fenton T, Cheng T, Furnari FB, Cavenee WK, et al. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 109: 3018-23. PMID 22323579 DOI: 10.1073/pnas.1121457109  0.92
2012 Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Current Cancer Drug Targets. 12: 197-209. PMID 22268382  0.92
2012 Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK, Furnari FB. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene. 31: 4054-66. PMID 22139077 DOI: 10.1038/onc.2011.563  0.92
2011 Li M, Mukasa A, Inda MM, Zhang J, Chin L, Cavenee W, Furnari F. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. The Journal of Experimental Medicine. 208: 2657-73. PMID 22162832 DOI: 10.1084/jem.20111102  0.92
2011 Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, ... ... Cavenee WK, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discovery. 1: 524-38. PMID 22145100 DOI: 10.1158/2159-8290.CD-11-0124  0.92
2011 Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T, Yiin JJ, Lu S, Keezer S, Fenton T, Furnari FB, Hamilton RL, Vuori K, Sarkaria JN, Nagane M, ... ... Cavenee WK, et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. The Journal of Clinical Investigation. 121: 4670-84. PMID 22080864 DOI: 10.1172/JCI58559  0.92
2011 Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 15984-9. PMID 21896743 DOI: 10.1073/pnas.1113416108  0.92
2011 Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee WK, Scott AM, Mischel PS, Hoogenraad NJ, Johns TG. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of Cell Science. 124: 2938-50. PMID 21878501 DOI: 10.1242/jcs.083295  0.92
2011 Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X, Tewari M, Furnari FB, Taniguchi T. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Molecular Cancer Research : McR. 9: 1100-11. PMID 21693595 DOI: 10.1158/1541-7786.MCR-11-0007  0.92
2011 Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Research. 71: 4055-60. PMID 21628493 DOI: 10.1158/0008-5472.CAN-11-0153  0.92
2011 Chumbalkar V, Latha K, Hwang Y, Maywald R, Hawley L, Sawaya R, Diao L, Baggerly K, Cavenee WK, Furnari FB, Bogler O. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR. Journal of Proteome Research. 10: 1343-52. PMID 21214269 DOI: 10.1021/pr101075e  0.92
2011 Wykosky J, Fenton T, Furnari F, Cavenee WK. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer. 30: 5-12. PMID 21192840  0.92
2011 Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, ... ... Cavenee WK, et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. The Journal of Clinical Investigation. 121: 161-73. PMID 21183793 DOI: 10.1172/JCI44798  0.92
2010 Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes & Development. 24: 1731-45. PMID 20713517 DOI: 10.1101/gad.1890510  0.92
2010 Huh SJ, Chen YL, Friedman SL, Liao J, Huang HJ, Cavenee WK, Robertson GP. KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. Journal of the National Cancer Institute. 102: 1131-47. PMID 20660366 DOI: 10.1093/jnci/djq218  0.92
2010 Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Inda MM, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. Plos One. 5: e10767. PMID 20532243 DOI: 10.1371/journal.pone.0010767  0.92
2010 Huang PH, Miraldi ER, Xu AM, Kundukulam VA, Del Rosario AM, Flynn RA, Cavenee WK, Furnari FB, White FM. Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Molecular Biosystems. 6: 1227-37. PMID 20461251 DOI: 10.1039/c001196g  0.92
2010 Wykosky J, Mukasa A, Furnari F, Cavenee WK. Escape from targeted inhibition: the dark side of kinase inhibitor therapy. Cell Cycle (Georgetown, Tex.). 9: 1661-2. PMID 20404502 DOI: 10.4161/cc.9.9.11592  0.92
2010 Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proceedings of the National Academy of Sciences of the United States of America. 107: 2616-21. PMID 20133782 DOI: 10.1073/pnas.0914356107  0.92
2009 Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, ... ... Cavenee WK, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Research. 69: 6889-98. PMID 19690143 DOI: 10.1158/0008-5472.CAN-09-0347  0.92
2009 Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E, Boothman DA, Furnari F, Cavenee WK, Bachoo RM, Burma S. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Research. 69: 4252-9. PMID 19435898 DOI: 10.1158/0008-5472.CAN-08-4853  0.92
2009 Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, Orchard SG, Clayton AH, Nice EC, Rothacker J, Catimel B, Cavenee WK, Old LJ, Stockert E, Ritter G, et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proceedings of the National Academy of Sciences of the United States of America. 106: 5082-7. PMID 19289842 DOI: 10.1073/pnas.0811559106  0.92
2009 James CD, Cavenee WK. Stem cells for treating glioblastoma: how close to reality? Neuro-Oncology. 11: 101. PMID 19237733 DOI: 10.1215/15228517-2009-016  0.92
2009 Read RD, Cavenee WK, Furnari FB, Thomas JB. A drosophila model for EGFR-Ras and PI3K-dependent human glioma. Plos Genetics. 5: e1000374. PMID 19214224 DOI: 10.1371/journal.pgen.1000374  0.92
2008 Roeb W, Boyer A, Cavenee WK, Arden KC. Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle (Georgetown, Tex.). 7: 837-41. PMID 18414034  0.92
2008 Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F, Cavenee WK, Hahn WC, Ichimura K, Collins VP, Chu GC, Stratton MR, et al. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 13: 355-64. PMID 18394558 DOI: 10.1016/j.ccr.2008.02.010  0.92
2008 Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, ... Cavenee WK, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 488-93. PMID 18223223 DOI: 10.1158/1078-0432.CCR-07-1966  0.92
2008 Barrera LO, Li Z, Smith AD, Arden KC, Cavenee WK, Zhang MQ, Green RD, Ren B. Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome Research. 18: 46-59. PMID 18042645 DOI: 10.1101/gr.6654808  0.92
2008 Liau LM, Cavenee WK. Editors' message to the readership Journal of Neuro-Oncology. 86: 1. DOI: 10.1007/s11060-007-9481-5  0.92
2008 Roeb W, Boyer A, Cavenee WK, Arden KC. Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor (Cell Cycle (2008) 7, (837-841)) Cell Cycle. 7: 3106.  0.92
2007 Huang PH, Cavenee WK, Furnari FB, White FM. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle (Georgetown, Tex.). 6: 2750-4. PMID 17986864  0.92
2007 Roeb W, Boyer A, Cavenee WK, Arden KC. PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proceedings of the National Academy of Sciences of the United States of America. 104: 18085-90. PMID 17986608 DOI: 10.1073/pnas.0708910104  0.92
2007 Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes & Development. 21: 2683-710. PMID 17974913 DOI: 10.1101/gad.1596707  0.92
2007 Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. 104: 12867-72. PMID 17646646 DOI: 10.1073/pnas.0705158104  0.92
2007 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 114: 97-109. PMID 17618441 DOI: 10.1007/s00401-007-0243-4  0.92
2007 Nagane M, Cavenee WK, Shiokawa Y. Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. Journal of Neurosurgery. 106: 407-16. PMID 17367063 DOI: 10.3171/jns.2007.106.3.407  0.92
2007 Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1911-25. PMID 17363548 DOI: 10.1158/1078-0432.CCR-06-1453  0.92
2007 Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee WK, Old LJ, Demetri GD, et al. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. The Journal of Clinical Investigation. 117: 346-52. PMID 17256054 DOI: 10.1172/JCI30446  0.92
2006 Finckenstein FG, Davicioni E, Osborn KG, Cavenee WK, Arden KC, Anderson MJ. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Transgenic Research. 15: 595-614. PMID 16952014 DOI: 10.1007/s11248-006-9011-9  0.92
2006 Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. 66: 7864-9. PMID 16912159 DOI: 10.1158/0008-5472.CAN-04-4392  0.92
2006 Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. The Journal of Biological Chemistry. 281: 26562-8. PMID 16829519 DOI: 10.1074/jbc.M605391200  0.92
2006 Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Di Vizio D, Divicio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee WK, Furnari FB, et al. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell. 9: 379-90. PMID 16697958 DOI: 10.1016/j.ccr.2006.03.028  0.92
2006 Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK, Chen W, Low WC. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. Journal of Neuro-Oncology. 76: 23-30. PMID 16155724 DOI: 10.1007/s11060-005-3280-7  0.92
2006 Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Di Vizio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee WK, Furnari FB, DePinho RA. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans (DOI:10.1016/j.ccr.2006.03.028) Cancer Cell. 10: 171. DOI: 10.1016/j.ccr.2006.07.012  0.92
2005 Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/NEJMoa051918  0.92
2005 Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6390-9. PMID 16144944 DOI: 10.1158/1078-0432.CCR-04-2653  0.92
2005 Okumura K, Zhao M, DePinho RA, Furnari FB, Cavenee WK. PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle (Georgetown, Tex.). 4: 540-2. PMID 15753657  0.92
2005 Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America. 102: 2703-6. PMID 15659546 DOI: 10.1073/pnas.0409370102  0.92
2005 Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics. 4: 101-12. PMID 15657358  0.92
2004 Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathology. 21: 53-6. PMID 15700833 DOI: 10.1007/BF02484510  0.92
2004 Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee WK, Dikic I, Bögler O. Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. Molecular and Cellular Biology. 24: 8981-93. PMID 15456872 DOI: 10.1128/MCB.24.20.8981-8993.2004  0.92
2004 Hosaka T, Biggs WH, Tieu D, Boyer AD, Varki NM, Cavenee WK, Arden KC. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proceedings of the National Academy of Sciences of the United States of America. 101: 2975-80. PMID 14978268 DOI: 10.1073/pnas.0400093101  0.92
2004 Waha A, Rodrigues FJ, Meyer-Puttlitz B, Cavenee WK, Huang THM, Wiestler OD, Yan PS. Methylation profiling identifies epigenetic markers for high-grade gliomas Cancer Genomics and Proteomics. 1: 209-214.  0.92
2003 Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Dias Neto E, Grivet M, Gruber A, Guimaraes PE, Hide W, Iseli C, Jongeneel CV, Kelso J, Nagai MA, Ojopi EP, ... ... Cavenee W, et al. The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proceedings of the National Academy of Sciences of the United States of America. 100: 13418-23. PMID 14593198 DOI: 10.1073/pnas.1233632100  0.48
2003 Cavenee WK. The recessive nature of dominance. Genes, Chromosomes & Cancer. 38: 322-5. PMID 14566850 DOI: 10.1002/gcc.10253  0.92
2003 Hu B, Guo P, Fang Q, Tao HQ, Wang D, Nagane M, Huang HJ, Gunji Y, Nishikawa R, Alitalo K, Cavenee WK, Cheng SY. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proceedings of the National Academy of Sciences of the United States of America. 100: 8904-9. PMID 12861074 DOI: 10.1073/pnas.1533394100  0.92
2003 Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America. 100: 8164-9. PMID 12808131 DOI: 10.1073/pnas.1332764100  0.92
2003 Cavenee WK. Preparing for serendipity. Cancer Biology & Therapy. 2: 213-5. PMID 12750567  0.92
2003 Schmidt MH, Furnari FB, Cavenee WK, Bögler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proceedings of the National Academy of Sciences of the United States of America. 100: 6505-10. PMID 12734385 DOI: 10.1073/pnas.1031790100  0.92
2003 Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK, Cheng SY. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. The American Journal of Pathology. 162: 1083-93. PMID 12651601 DOI: 10.1016/S0002-9440(10)63905-3  0.92
2002 Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Research. 62: 6764-9. PMID 12438278  0.92
2002 Cavenee WK. Muscling in on rhabdomyosarcoma. Nature Medicine. 8: 1200-1. PMID 12411939 DOI: 10.1038/nm1102-1200  0.92
2002 Nakae J, Biggs WH, Kitamura T, Cavenee WK, Wright CV, Arden KC, Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nature Genetics. 32: 245-53. PMID 12219087 DOI: 10.1038/ng890  0.92
2002 De Smet C, Nishimori H, Furnari FB, Bögler O, Huang HJ, Cavenee WK. A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. Journal of Neurochemistry. 81: 575-88. PMID 12065666 DOI: 10.1046/j.1471-4159.2002.00847.x  0.92
2002 Cavenee WK. Genetics and new approaches to cancer therapy. Carcinogenesis. 23: 683-6. PMID 12016138  0.92
2002 Costello JF, Plass C, Cavenee WK. Restriction landmark genome scanning. Methods in Molecular Biology (Clifton, N.J.). 200: 53-70. PMID 11951655 DOI: 10.1385/1-59259-182-5:053  0.92
2002 Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. International Journal of Cancer. Journal International Du Cancer. 98: 398-408. PMID 11920591 DOI: 10.1002/ijc.10189  0.92
2002 Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. Journal of Neuropathology and Experimental Neurology. 61: 215-25; discussion 2. PMID 11895036  0.92
2002 Steinbach JP, Supra P, Huang HJ, Cavenee WK, Weller M. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathology (Zurich, Switzerland). 12: 12-20. PMID 11770895  0.92
2001 Cardó-Vila M, Arden KC, Cavenee WK, Pasqualini R, Arap W. Is annexin 7 a tumor suppressor gene in prostate cancer? The Pharmacogenomics Journal. 1: 92-4. PMID 11911446  0.92
2001 Guo P, Xu L, Pan S, Brekken RA, Yang ST, Whitaker GB, Nagane M, Thorpe PE, Rosenbaum JS, Su Huang HJ, Cavenee WK, Cheng SY. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Research. 61: 8569-77. PMID 11731444  0.92
2001 Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. Journal of Neurosurgery. 95: 472-9. PMID 11565870 DOI: 10.3171/jns.2001.95.3.0472  0.92
2001 Klingler-Hoffmann M, Fodero-Tavoletti MT, Mishima K, Narita Y, Cavenee WK, Furnari FB, Huang HJ, Tiganis T. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. The Journal of Biological Chemistry. 276: 46313-8. PMID 11514572 DOI: 10.1074/jbc.M106571200  0.92
2001 Chuenkova MV, Furnari FB, Cavenee WK, Pereira MA. Trypanosoma cruzi trans-sialidase: a potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling. Proceedings of the National Academy of Sciences of the United States of America. 98: 9936-41. PMID 11481434 DOI: 10.1073/pnas.161298398  0.92
2001 Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Research. 61: 5355-61. PMID 11454674  0.92
2001 Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WK. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Research. 61: 5349-54. PMID 11454673  0.92
2001 Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. Malignant glioma: genetics and biology of a grave matter. Genes & Development. 15: 1311-33. PMID 11390353 DOI: 10.1101/gad.891601  0.92
2001 Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis : An International Journal On Programmed Cell Death. 6: 191-7. PMID 11388668 DOI: 10.1023/A:1011336726649  0.92
2001 Biggs WH, Cavenee WK, Arden KC. Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. Mammalian Genome : Official Journal of the International Mammalian Genome Society. 12: 416-25. PMID 11353388 DOI: 10.1007/s003350020002  0.92
2001 Fan X, Furnari FB, Cavenee WK, Castresana JS. Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. International Journal of Oncology. 18: 1023-6. PMID 11295051  0.92
2001 Anderson MJ, Shelton GD, Cavenee WK, Arden KC. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proceedings of the National Academy of Sciences of the United States of America. 98: 1589-94. PMID 11171995 DOI: 10.1073/pnas.98.4.1589  0.92
2001 Nagane M, Lin H, Cavenee WK, Huang HJ. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Letters. 162: S17-S21. PMID 11164186 DOI: 10.1016/S0304-3835(00)00648-0  0.92
2000 Bögler O, Furnari FB, Kindler-Roehrborn A, Sykes VW, Yung R, Huang HJ, Cavenee WK. SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro-Oncology. 2: 6-15. PMID 11302255  0.92
2000 Costello JF, Plass C, Cavenee WK. Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathology. 17: 49-56. PMID 11210171  0.92
2000 Nishimori H, Nishikawa R, Fujimaki T, Nakagomi T, Matsutani M, Huang HJ, Cavenee WK. Analysis of the p300/CBP-Associated Factor (PCAF) gene in astrocytic tumors. Journal of Neuro-Oncology. 46: 17-22. PMID 10896202 DOI: 10.1023/A:1006404110073  0.92
2000 Mishima K, Mazar AP, Gown A, Skelly M, Ji XD, Wang XD, Jones TR, Cavenee WK, Huang HJ. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proceedings of the National Academy of Sciences of the United States of America. 97: 8484-9. PMID 10890917 DOI: 10.1073/pnas.150239497  0.92
2000 Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, Tu X, Baserga R. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene. 19: 2687-94. PMID 10851068 DOI: 10.1038/sj.onc.1203587  0.92
2000 Cavenee WK. High-grade gliomas with chromosome 1p loss. Journal of Neurosurgery. 92: 1080-1. PMID 10839286  0.92
2000 Amler LC, Bauer A, Corvi R, Dihlmann S, Praml C, Cavenee WK, Schwab M, Hampton GM. Identification and characterization of novel genes located at the t(1;15)(p36.2;q24) translocation breakpoint in the neuroblastoma cell line NGP. Genomics. 64: 195-202. PMID 10729226 DOI: 10.1006/geno.1999.6097  0.92
2000 Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Research. 60: 847-53. PMID 10706092  0.92
2000 Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, ... ... Cavenee WK, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics. 24: 132-8. PMID 10655057 DOI: 10.1038/72785  0.92
1999 Nagane M, Huang HJ, Cavenee WK. Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2: 30-37. PMID 11504467 DOI: 10.1054/drup.1998.0062  0.92
1999 Valter MM, Hügel A, Huang HJ, Cavenee WK, Wiestler OD, Pietsch T, Wernert N. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Research. 59: 5608-14. PMID 10554042  0.92
1999 Robertson GP, Huang HJ, Cavenee WK. Identification and validation of tumor suppressor genes. Molecular Cell Biology Research Communications : McBrc. 2: 1-10. PMID 10527883 DOI: 10.1006/mcbr.1999.0141  0.92
1999 Knudsen KE, Weber E, Arden KC, Cavenee WK, Feramisco JR, Knudsen ES. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene. 18: 5239-45. PMID 10498874 DOI: 10.1038/sj.onc.1202910  0.92
1999 Robertson GP, Herbst RA, Nagane M, Huang HJ, Cavenee WK. The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci. Cancer Research. 59: 3596-601. PMID 10446968  0.92
1999 Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene. 18: 3936-43. PMID 10435616 DOI: 10.1038/sj.onc.1202774  0.92
1999 Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proceedings of the National Academy of Sciences of the United States of America. 96: 7421-6. PMID 10377430 DOI: 10.1073/pnas.96.13.7421  0.92
1999 Smiraglia DJ, Frühwald MC, Costello JF, McCormick SP, Dai Z, Peltomäki P, O'Dorisio MS, Cavenee WK, Plass C. A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. Genomics. 58: 254-62. PMID 10373323 DOI: 10.1006/geno.1999.5840  0.92
1999 Knudsen KE, Cavenee WK, Arden KC. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Research. 59: 2297-301. PMID 10344732  0.92
1999 Christov C, Gherardi RK. Vascular endothelial growth factor (VEGF) likely contributes to oligodendroglioma angiogenesis. Acta Neuropathologica. 97: 429-32. PMID 10208285 DOI: 10.1007/s004010051009  0.4
1999 Wang D, Huang HJ, Kazlauskas A, Cavenee WK. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Research. 59: 1464-72. PMID 10197615  0.92
1999 Bögler O, Nagane M, Gillis J, Huang HJ, Cavenee WK. Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 10: 73-86. PMID 10074901  0.92
1999 Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Research. 59: 798-802. PMID 10029065  0.92
1998 Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK, Matsutani M. Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathologica. 96: 453-62. PMID 9829808 DOI: 10.1007/s004010050919  0.92
1998 Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Research. 58: 5002-8. PMID 9823298  0.92
1998 Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. The American Journal of Pathology. 153: 1239-48. PMID 9777955 DOI: 10.1016/S0002-9440(10)65668-4  0.92
1998 Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ, Cavenee WK. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proceedings of the National Academy of Sciences of the United States of America. 95: 9418-23. PMID 9689095 DOI: 10.1073/pnas.95.16.9418  0.92
1998 Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. The Journal of Biological Chemistry. 273: 20213-22. PMID 9685369 DOI: 10.1074/jbc.273.32.20213  0.92
1998 Carethers JM, Furnari FB, Zigman AF, Lavine JE, Jones MC, Graham GE, Teebi AS, Huang HJ, Ha HT, Chauhan DP, Chang CL, Cavenee WK, Boland CR. Absence of PTEN/MMAC1 germ-line mutations in sporadic Bannayan-Riley-Ruvalcaba syndrome. Cancer Research. 58: 2724-6. PMID 9661881  0.92
1998 Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proceedings of the National Academy of Sciences of the United States of America. 95: 5724-9. PMID 9576951 DOI: 10.1073/pnas.95.10.5724  0.92
1998 Anderson MJ, Viars CS, Czekay S, Cavenee WK, Arden KC. Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics. 47: 187-99. PMID 9479491 DOI: 10.1006/geno.1997.5122  0.92
1997 Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK. Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway. Oncogene. 15: 2013-20. PMID 9366518 DOI: 10.1038/sj.onc.1201389  0.92
1997 Furnari FB, Lin H, Huang HS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proceedings of the National Academy of Sciences of the United States of America. 94: 12479-84. PMID 9356475 DOI: 10.1073/pnas.94.23.12479  0.92
1997 Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proceedings of the National Academy of Sciences of the United States of America. 94: 12081-7. PMID 9342366 DOI: 10.1073/pnas.94.22.12081  0.92
1997 Larson AA, Liao SY, Stanbridge EJ, Cavenee WK, Hampton GM. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Research. 57: 4171-6. PMID 9331069  0.92
1997 Plass C, Weichenhan D, Catanese J, Costello JF, Yu F, Yu L, Smiraglia D, Cavenee WK, Caligiuri MA, deJong P, Held WA. An arrayed human not I-EcoRV boundary library as a tool for RLGS spot analysis. Dna Research : An International Journal For Rapid Publication of Reports On Genes and Genomes. 4: 253-5. PMID 9330914  0.92
1997 Larson AA, Kern S, Curtiss S, Gordon R, Cavenee WK, Hampton GM. High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Research. 57: 4082-90. PMID 9307297  0.92
1997 Nagane M, Huang HJ, Cavenee WK. Advances in the molecular genetics of gliomas. Current Opinion in Oncology. 9: 215-22. PMID 9229142  0.92
1997 Herbst RA, Gutzmer R, Matiaske F, Mommert S, Kapp A, Weiss J, Arden KC, Cavenee WK. Further evidence for ultraviolet light induction of CDKN2 (p16INK4) mutations in sporadic melanoma in vivo. The Journal of Investigative Dermatology. 108: 950. PMID 9182829  0.92
1997 Ivanchuk SM, Eng C, Cavenee WK, Mulligan LM. The expression of RET and its multiple splice forms in developing human kidney. Oncogene. 14: 1811-8. PMID 9150387 DOI: 10.1038/sj.onc.1201016  0.92
1997 Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang HJ, Cavenee WK. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Research. 57: 1250-4. PMID 9102208  0.92
1997 Arap W, Knudsen ES, Wang JY, Cavenee WK, Huang HJ. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma. Oncogene. 14: 603-9. PMID 9053859 DOI: 10.1038/sj.onc.1200870  0.92
1997 Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK, Wiestler OD. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathologica. 93: 109-17. PMID 9039457 DOI: 10.1007/s004010050591  0.92
1997 Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. The Journal of Biological Chemistry. 272: 2927-35. PMID 9006938 DOI: 10.1074/jbc.272.5.2927  0.92
1997 Cavenee W, Naeane M, Klmebeil C, Lm H, Nishikawa R, Huan CM, Gill GN, Wiley HS, Huang HJS. Tumorigenic enhancement by mutant egfr mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signalling Faseb Journal. 11: A1448.  0.92
1996 Besnard-Guérin C, Winqvist R, Newsham I, Cavenee WK. Population variation at the polymorphic ApaLI restriction enzyme site in intron 5 of the WT1 gene Clinical Genetics. 50: 555-557. PMID 9147899  0.92
1996 Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, Huang HJS. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis Cancer Research. 56: 5079-5086. PMID 8895767  0.92
1996 Arden KC, Anderson MJ, Finckenstein FG, Czekay S, Cavenee WK. Detection of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma using the reverse transcriptase-polymerase chain reaction. Genes, Chromosomes & Cancer. 16: 254-60. PMID 8875239 DOI: 10.1002/(SICI)1098-2264(199608)16:4<254::AID-GCC5>3.0.CO;2-X  0.92
1996 Furnari FB, Huang HJ, Cavenee WK. Molecular biology of malignant degeneration of astrocytoma. Pediatric Neurosurgery. 24: 41-9. PMID 8817614  0.92
1996 Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HS. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. The Journal of Biological Chemistry. 271: 25639-45. PMID 8810340 DOI: 10.1074/jbc.271.41.25639  0.92
1996 Wasserman LM, Newsham I, Huang HJS, Cavenee WK. cAMP effects on myogenic gene expression in rhabdomyosarcoma cells Experimental Cell Research. 227: 55-62. PMID 8806451 DOI: 10.1006/excr.1996.0249  0.92
1996 Black PM, Nomura K, Cavenee WK, Kakizoe T, Mukai K. Report of the ninth international symposium of the foundation for promotion of cancer research: Basic and clinical research in brain tumors Japanese Journal of Clinical Oncology. 26: 277-282. PMID 8765189  0.92
1996 Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJS. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors Cancer Research. 56: 3859-3861. PMID 8752145  0.92
1996 Cheng SY, Huang HJS, Nagane M, Ji XD, Wang D, Shih CCY, Arap W, Huang CM, Cavenee WK. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor Proceedings of the National Academy of Sciences of the United States of America. 93: 8502-8507. PMID 8710899 DOI: 10.1073/pnas.93.16.8502  0.92
1996 Hampton GM, Larson AA, Baergen RN, Sommers RL, Kern S, Cavenee WK. Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 93: 6704-9. PMID 8692882  0.92
1996 Larson AA, Kern S, Sommers RL, Yokota J, Cavenee WK, Hampton GM. Analysis of replication error (RER+) phenotypes in cervical carcinoma. Cancer Research. 56: 1426-31. PMID 8640835  0.92
1996 Costello JF, Berger MS, Huang HJS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation Cancer Research. 56: 2405-2410. PMID 8625319  0.92
1996 Besnard-Guérin C, Newsham I, Winqvist R, Cavenee WK. A common region of loss of heterozygosity in Wilms' tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5 Human Genetics. 97: 163-170. PMID 8566947 DOI: 10.1007/BF02265259  0.92
1996 Dias P, Singh S, Shih C, Wu C, Cavenee W, Tirabosco R, Triche T, Huang E. Diagnostic utility of a monoclonal antibody that is highly specific human MyoD (Myf3) Faseb Journal. 10: A1295.  0.92
1995 Furnari FB, Huang HJ, Cavenee WK. Genetics and malignant progression of human brain tumours. Cancer Surveys. 25: 233-75. PMID 8718522  0.92
1995 Solomon E, Ponder BA, Cavenee WK. Genetics and cancer: a second look. Introduction Cancer Surveys. 25: 1-2. PMID 8718509  0.92
1995 Bögler O, Huang HJ, Kleihues P, Cavenee WK. The p53 gene and its role in human brain tumors Glia. 15: 308-327. PMID 8586466  0.92
1995 Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Research. 55: 1351-4. PMID 7882335  0.92
1995 Cavenee WK, White RL. The genetic basis of cancer. Scientific American. 272: 72-9. PMID 7871410  0.92
1995 Van Meir EG, Roemer K, Diserens AC, Kikuchi T, Rempel SA, Haas M, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK. Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 92: 1008-12. PMID 7862624 DOI: 10.1073/pnas.92.4.1008  0.92
1995 Winqvist R, Hampton GM, Mannermaa A, Blanco G, Alavaikko M, Kiviniemi H, Taskinen PJ, Evans GA, Wright FA, Newsham I, Cavenee WK. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis Cancer Research. 55: 2660-2664. PMID 7780982  0.92
1995 Herbst RA, Larson A, Weiss J, Cavenee WK, Hampton GM, Arden KC. A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma Cancer Research. 55: 2494-2496. PMID 7780954  0.92
1995 Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Su Huang HJ. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Research. 55: 1941-5. PMID 7728764  0.92
1995 Besnard-Guerin C, Cavenee W, Newsham I. The t(11;22)(p15.5;q11.23) in a retroperitoneal rhabdoid tumor also includes a regional deletion distal to CRYBB2 on 22q Genes Chromosomes and Cancer. 13: 145-150. PMID 7669732 DOI: 10.1002/gcc.2870130302  0.92
1995 Bishop JM, Brinkley BR, Cavenee W, Kaufman DG, Olden K, Shubik P, Stevenson DE, Tennant RW, Trump BF, Wogan GN, Wood AW, Yuspa SH. Ninth Aspen Cancer Conference: Mechanisms of toxicity and carcinogenesis Molecular Carcinogenesis. 13: 203-209. PMID 7646758 DOI: 10.1002/mc.2940130402  0.92
1995 Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification - Rearrangement in human glioblastomas International Journal of Cancer. 62: 145-148. PMID 7622287 DOI: 10.1002/ijc.2910620206  0.92
1995 Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, Carter SL, Rosenberg AL, Schwartz GF, Shiloh Y, Cavenee WK. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Research. 55: 3003-7. PMID 7606718  0.92
1995 Newsham I, Kindler-Rohrborn A, Daub D, Cavenee W. A constitutional BWS-related t(11;16) chromosome translocation occurring in the same region of chromosome 16 implicated in Wilms' tumors Genes Chromosomes and Cancer. 12: 1-7. PMID 7534105 DOI: 10.1002/gcc.2870120102  0.92
1994 Herbst RA, Weiss J, Ehnis A, Cavenee WK, Arden KC. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression Cancer Research. 54: 3111-3114. PMID 8205526  0.92
1994 Hampton GM, Mannermaa A, Winquist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee WK, Evans GA. Loss of heterozygosity in sporadic human breast carcinoma: A common region between 11q22 and 11q23.3 Cancer Research. 54: 4586-4589. PMID 8062246  0.92
1994 Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJS. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proceedings of the National Academy of Sciences of the United States of America. 91: 7727-7731. PMID 8052651 DOI: 10.1073/pnas.91.16.7727  0.92
1994 Gessler M, König A, Arden K, Grundy P, Orkin S, Sallan S, Peters C, Ruyle S, Mandell J, Li F, Cavenee W, Bruns G. Infrequent mutation of the WT1 gene in 77 Wilms' tumors Human Mutation. 3: 212-222. PMID 8019557  0.92
1994 De Plaen E, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, Chomez P, De Backer O, Boon T, Arden K, Cavenee W, Brasseur R. Structure, chromosomal localization, and expression of 12 genes of the MAGE family Immunogenetics. 40: 360-369. PMID 7927540 DOI: 10.1007/BF01246677  0.92
1994 Adesina AM, Nalbantoglu J, Cavenee WK. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Research. 54: 5649-51. PMID 7923211  0.92
1994 Herbst RA, Nobori T, Cavenee WK, Carson DA, Arden KC. Dinucleotide repeat polymorphism adjacent to CDKN2 Human Molecular Genetics. 3: 2265. PMID 7881438  0.92
1994 Weiss J, Cavenee WK, Herbst RA, Jung EG, Arden KC. Point mutations and allelic loss in the TP53 locus of cutaneous malignant melanomas Archives of Dermatological Research. 286: 417-419. PMID 7818283 DOI: 10.1007/BF00371803  0.92
1994 Van Meir EG, Polverini PJ, Chazin VR, Huang HJS, De Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells Nature Genetics. 8: 171-176. PMID 7531056 DOI: 10.1038/ng1094-171  0.92
Show low-probability matches.